{"corpus_id":205906485,"paper_sha":"daafc2944e3630a3693598e8085f3cae241c891a","doi":"10.1002/hep.29477","arxiv_id":null,"pmid":28833331,"pmcid":"5947654","mag_id":2746863374,"dblp_id":null,"acl_id":null,"title":"A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","year":2018,"publication_date":"2018-01-29","venue":"Hepatology","journal":{"name":"Hepatology (Baltimore, Md.)","pages":"1754 - 1767","volume":"67"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial, Phase II","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":28,"citation_count":572,"influential_citation_count":11,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Biomarkers","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D015415"},{"d":"CCR5 Receptor Antagonists","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D065100"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Imidazoles","mj":false,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D007093"},{"d":"Liver","mj":false,"qs":[{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D008099"},{"d":"Liver Cirrhosis","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"},{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D008103"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Non-alcoholic Fatty Liver Disease","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"},{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D065626"},{"d":"Sulfoxides","mj":false,"ui":"D013454"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"}],"chemicals":[{"n":"Biomarkers","ui":"D015415","reg":"0"},{"n":"CCR5 Receptor Antagonists","ui":"D065100","reg":"0"},{"n":"Imidazoles","ui":"D007093","reg":"0"},{"n":"Sulfoxides","ui":"D013454","reg":"0"},{"n":"cenicriviroc","ui":"C506967","reg":"15C116UA4Y"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.29477","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/daafc2944e3630a3693598e8085f3cae241c891a","s2_open_access_license":"CCBYNCND","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of CC chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double‐blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score (NAS) ≥4, and LF (stages 1‐3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome was ≥2‐point improvement in NAS and no worsening of fibrosis at year 1. Key secondary outcomes were: resolution of steatohepatitis (SH) and no worsening of fibrosis; improvement in fibrosis by ≥1 stage and no worsening of SH. Biomarkers of inflammation and adverse events were assessed. Full study recruitment was achieved. The primary endpoint of NAS improvement in the intent‐to‐treat population and resolution of SH was achieved in a similar proportion of subjects on CVC (N = 145) and placebo (N = 144; 16% vs. 19%, P = 0.52 and 8% vs. 6%, P = 0.49, respectively). However, the fibrosis endpoint was met in significantly more subjects on CVC than placebo (20% vs. 10%; P = 0.02). Treatment benefits were greater in those with higher disease activity and fibrosis stage at baseline. Biomarkers of systemic inflammation were reduced with CVC. Safety and tolerability of CVC were comparable to placebo. Conclusion: After 1 year of CVC treatment, twice as many subjects achieved improvement in fibrosis and no worsening of SH compared with placebo. Given the urgent need to develop antifibrotic therapies in NASH, these findings warrant phase 3 evaluation. (Hepatology 2018;67:1754‐1767).","claims":[{"public_id":"cl_eb044e6c9cd66ca20672653115c76c70","status":"active","text":"Cenicriviroc and placebo produced similar rates of NAS improvement and steatohepatitis resolution at year 1 in the intent-to-treat population.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_eb044e6c9cd66ca20672653115c76c70"},{"public_id":"cl_f0ab0cad8b69aa82e6e3bc175b23c840","status":"active","text":"Systemic inflammation biomarkers were reduced with cenicriviroc, and safety and tolerability were comparable to placebo.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f0ab0cad8b69aa82e6e3bc175b23c840"},{"public_id":"cl_314419cc099e5ae06c7e0bd1145997f9","status":"active","text":"The fibrosis endpoint was achieved in significantly more subjects receiving cenicriviroc than placebo.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_314419cc099e5ae06c7e0bd1145997f9"},{"public_id":"cl_0814d4c3ac9a84a6161e01b5a311fde3","status":"active","text":"Treatment benefits were greater in participants with higher baseline disease activity and fibrosis stage.","confidence":0.88,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_0814d4c3ac9a84a6161e01b5a311fde3"}],"concepts":[{"public_id":"co_1bf1321268f666855f1cf652f7d8bbaa","status":"active","name":"fibrosis endpoint","description":"The primary fibrosis-related outcome defined by improvement in fibrosis without worsening of steatohepatitis.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1bf1321268f666855f1cf652f7d8bbaa"},{"public_id":"co_353ef67ac98a33445dca00bb4c34c0fd","status":"active","name":"liver fibrosis","description":"Excessive accumulation of fibrous tissue in the liver, graded by stage in this trial.","types":["disease feature","outcome"],"aliases":["LF","fibrosis"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_353ef67ac98a33445dca00bb4c34c0fd"},{"public_id":"co_36210605ade2af18157939082e218a06","status":"active","name":"cenicriviroc","description":"A dual antagonist of C-C chemokine receptor types 2 and 5 evaluated as a treatment for nonalcoholic steatohepatitis with fibrosis.","types":["drug","therapeutic agent"],"aliases":["CVC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_36210605ade2af18157939082e218a06"},{"public_id":"co_54d6d69d1fee369286819bd817158c18","status":"active","name":"systemic inflammation biomarkers","description":"Biological markers in blood or other systemic samples used to assess inflammatory activity.","types":["biomarker","measurement"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_54d6d69d1fee369286819bd817158c18"},{"public_id":"co_77e0ee2ff01280ffa1c6a47c59f94977","status":"active","name":"higher disease activity","description":"Greater baseline severity of nonalcoholic steatohepatitis as reflected by higher disease activity scores.","types":["baseline characteristic"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_77e0ee2ff01280ffa1c6a47c59f94977"},{"public_id":"co_7a7d15bb1411c9b23034523666e5c0d4","status":"active","name":"fibrosis stage","description":"The baseline stage of liver fibrosis used to stratify disease severity.","types":["baseline characteristic","measurement"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7a7d15bb1411c9b23034523666e5c0d4"},{"public_id":"co_ceae8c7d02b32ac22233459138b2d825","status":"active","name":"placebo","description":"An inactive comparator used in the randomized controlled trial.","types":["control","comparator"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ceae8c7d02b32ac22233459138b2d825"},{"public_id":"co_d3021bb2e26af01a051aead3fca986fb","status":"active","name":"nonalcoholic steatohepatitis","description":"An inflammatory form of nonalcoholic fatty liver disease characterized by liver injury and steatosis.","types":["disease","condition"],"aliases":["NASH","steatohepatitis","SH"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d3021bb2e26af01a051aead3fca986fb"},{"public_id":"co_f38f9a7bbeff00033b79921dbb99b7a6","status":"active","name":"nonalcoholic fatty liver disease activity score","description":"A composite histologic score used to assess disease activity in nonalcoholic steatohepatitis.","types":["measurement","clinical score"],"aliases":["NAS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f38f9a7bbeff00033b79921dbb99b7a6"},{"public_id":"co_ff5cf6c8a7389bf7d8401e10dde8e01f","status":"active","name":"safety and tolerability","description":"Assessment of adverse events and treatment acceptability during drug administration.","types":["safety outcome","outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ff5cf6c8a7389bf7d8401e10dde8e01f"}],"external_ids":{"DOI":"10.1002/hep.29477","ArXiv":null,"PubMed":28833331,"PubMedCentral":"5947654","MAG":2746863374,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.29477","landing_url":"https://www.semanticscholar.org/paper/daafc2944e3630a3693598e8085f3cae241c891a","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":638553,"paper_uid":"d43beec1-49bc-48e9-ba41-9169800b5199","canonical_identity":{"paper_id":638553,"paper_uid":"d43beec1-49bc-48e9-ba41-9169800b5199","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/205906485"}